# ABACUS MEDICINE A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/abacusmedicine). ## Overview Abacus Medicine A/S is a Denmark-based pharmaceutical wholesaler and service company focused on parallel trade and distribution of medicinal products across European markets. Through its group structure, it supplies pharmacies, hospitals, healthcare providers and other wholesalers with pharmaceuticals and related products, while also operating related healthcare businesses. ## Products & services • Wholesale trade in pharmaceutical and related products • Supply of medicines to pharmacies and hospitals • Distribution services for healthcare customers • Parallel trade in branded pharmaceuticals • Related pharmaceutical services and group operations - **Pharmaceutical wholesale** (75%) — Bulk distribution and resale of medicinal products and related goods to professional healthcare buyers. - **Parallel trade pharmaceuticals** (20%) — Cross-border sourcing and redistribution of medicines within regulated European markets. - **Healthcare services** (5%) — Ancillary services tied to pharmaceutical supply and related healthcare operations. - Wholesale trade in pharmaceutical and related products - Supply of medicines to pharmacies and hospitals - Distribution services for healthcare customers - Parallel trade in branded pharmaceuticals - Related pharmaceutical services and group operations ## Customers Abacus Medicine sells primarily to professional healthcare buyers rather than end consumers. Its customer base includes wholesalers and pharmacies, and it also serves hospitals and other healthcare providers through its distribution activities. These customers buy from Abacus Medicine to secure access to regulated medicines, manage supply continuity, and source products across European markets. - **Wholesalers** (primary) — Buy pharmaceuticals in bulk for redistribution; important because the annual report identifies them as a main customer group. - **Pharmacies** (primary) — Purchase medicines to meet patient demand and manage stock availability across regulated markets. - **Hospitals** (secondary) — Source pharmaceutical products for institutional use and inventory continuity. - **Healthcare providers** (secondary) — Buy related products and services tied to medicines distribution and access. - Wholesalers buying medicines for onward distribution - Pharmacies seeking reliable product availability - Hospitals sourcing regulated pharmaceuticals - Healthcare providers needing supply continuity - Professional buyers in cross-border pharma markets ## Geography Abacus Medicine is headquartered in Copenhagen, Denmark, and operates through a European pharmaceutical trading and distribution network. The annual report references group operations in Ireland and Germany, indicating a multi-country footprint that supports cross-border supply and sourcing. Its business is exposed to regulatory, pricing and logistics conditions across the European markets in which it operates. - Headquartered in Copenhagen, Denmark - Operates a European cross-border pharma network - References activities in Ireland and Germany - Business depends on EU pharmaceutical trade rules - Geography shapes sourcing, pricing and logistics ## Strategy The company’s strategic position is built around sourcing, distributing and trading pharmaceuticals across regulated European markets. Its business model depends on maintaining reliable supplier access, efficient logistics and broad customer coverage across professional healthcare channels. Related services and acquisitions also extend the group beyond pure wholesale trade. - **Protect access to supply and market coverage** (short-term) — Parallel trade and wholesale depend on product availability, regulatory access and efficient distribution. - **Strengthen customer and credit risk management** (short-term) — The business invoices professional buyers and uses factoring to limit receivable risk. - **Build adjacent healthcare capabilities** (medium-term) — Related products and services can broaden the business beyond core wholesale trade. - Expand cross-border pharmaceutical trade capabilities - Maintain reliable supply into pharmacies and hospitals - Use logistics and sourcing scale to support availability - Diversify through related healthcare activities - Manage receivables through factoring and credit controls ## Risks Abacus Medicine is exposed to pharmaceutical pricing pressure, regulatory changes and supply disruptions inherent in cross-border drug trading. Customer concentration in professional healthcare channels also creates credit and working-capital risk, although factoring reduces some receivable exposure. Earnings can also be affected by inventory valuation, contingent consideration and other judgment-based accounting estimates. - **Regulatory change in parallel trade** [high] — Pharmaceutical wholesale and cross-border trade depend on national and EU healthcare rules. - **Supply chain disruption** [high] — The business relies on timely access to medicines and efficient logistics across markets. - **Customer credit risk** [medium] — Sales are made to wholesalers, pharmacies and hospitals, and payment patterns must be monitored. - **Inventory valuation risk** [medium] — Medicines inventory must be carried at net realisable value and can require write-downs. - Regulatory changes can restrict parallel trade economics - Supply disruptions can limit product availability - Pharmaceutical pricing pressure can compress trading economics - Customer credit risk remains despite factoring arrangements - Inventory and valuation estimates affect reported earnings ## Accounting Inventory valuation is important because pharmaceutical products can require write-downs to net realisable value when pricing or sell-through changes. The group also uses factoring arrangements on customer invoices, which affects trade receivables, cash conversion and disclosure of credit risk. In addition, contingent consideration from acquisitions is measured at fair value, making reported liabilities sensitive to turnover assumptions and discount rates. - **Inventory valuation** — Affects gross profit and working capital - **Factoring agreements** — Affects trade receivables and liquidity - **Contingent consideration** — Affects provisions and finance costs - **Expected credit losses** — Affects impairment charges on receivables - Inventory net realisable value affects write-down expense - Factoring changes receivable risk and liquidity presentation - Credit loss estimates depend on customer payment patterns - Contingent consideration is remeasured using valuation inputs - Share-based payments and provisions require management judgment --- *Last updated: 2026-10-24T14:59:36.894229+00:00*